BiotechTube
Exo Therapeutics

Exo Therapeutics

Cambridge, United States· Est.
exo-therapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $160M

Overview

Exo Therapeutics, founded in 2017 and based in Cambridge, Massachusetts, is a private, pre-clinical stage biotech developing a new class of small molecule drugs. Its core innovation is targeting exosites—distinct, often allosteric sites on enzymes—to achieve selective inhibition or modulation, thereby tackling previously 'undruggable' targets. The company's pipeline, led by a TBK1 inhibitor program for inflammatory diseases, is built on its ExoSight™ discovery platform and is supported by a team with deep pharmaceutical industry expertise in drug development.

OncologyInflammation

Technology Platform

ExoSight™ platform for discovering small molecule drugs that target exosites (allosteric regulatory sites) on enzymes to modulate activity with high selectivity.

Funding History

2
Total raised:$160M
Series B$82M
Series A$78M

Opportunities

The exosite approach could unlock a vast array of previously 'undruggable' enzyme targets, creating first-in-class therapies for high-need diseases in large markets like oncology and inflammation.
Successful validation of the platform could also make Exo an attractive partner or acquisition target for larger pharmaceutical companies seeking novel discovery engines.

Risk Factors

The core scientific risk is that the novel exosite-targeting approach may fail to yield clinically effective or safe drugs, as it is an unproven modality.
Financially, as a pre-revenue, pre-clinical company, Exo is highly dependent on raising capital in a competitive funding environment to sustain operations and advance its pipeline.

Competitive Landscape

Exo competes with numerous biotechs and pharmas developing small molecule inhibitors for kinases and other enzymes in oncology/inflammation. Its differentiation lies in its specific focus on exosite targeting versus active sites. It also competes broadly with other modalities (e.g., PROTACs, molecular glues, biologics) aiming to drug challenging targets.

More companies in United States →